Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors


Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.

Aim(s): Case series illustrating the possible use of targeted therapies in the first line treatment of advanced pNETS.

Materials and methods: We describe case of 4 chemo-naïve patients (age at diagnosis 46-71; 3 male, 1 female) with advanced pNETs. These patients were initially unresectable, deemed palliative or refused chemotherapy as first line. Targeted therapy was commenced between 2011 – 2012.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Kavan P

Authors: Rho Y, Gilabert M, McLean J, Kavan P,

Keywords: targeted therapy, sunitinib, everolimus, PNET,

To read the full abstract, please log into your ENETS Member account.